Johnson & Johnson to seek approval for 10 potential blockbusters in next 4 years
BUZ INVESTORS Johnson & Johnson to seek approval Johnson & Johnson (JNJ), -0.41% said Wednesday that it, along with its Janssen Pharmaceutical Companies, plans to file for regulatory approval 10 new potential blockbuster drugs between this year and 2021. The company said it also plans more than 50 line extensions of existing and new medicines through 2021. “With a growing core business of differentiated medicines and a strong line-up of innovative products expected to launch or file over the next five years, we are leading the industry in advancing the health of patients around the world,” said J&J Chief Executive Alex Gorsky.
Johnson & Johnson to seek approval
In this morning’s Pharmaceutical Business Review, Johnson & Johnson’s (JNJ)-0.6%) Worldwide Chairman, Pharmaceuticals, Joaquin Duato said 75% of the company’s growth in drug sales were driven by volume growth as opposed to price hikes over the period 2012 – 2016.
He added that the company expects a re-acceleration of growth in its pharma business this year which should continue through 2021.
Source: The Fly
|Industry:||Drug Manufacturers » Drug Manufacturers – Major NAICS: 325412 SIC: 2834|
|Compare:||OTCPK:(RHHBY), NYSE:(PFE), OTCPK:(NVSEF), NYSE:(MRK), NYSE:(SNY), OTCPK:(GLAXF), NYSE:(ABBV), OTCPK:(BAYZF), NYSE:(BMY), NYSE:(LLY), NYSE:(AZN), OTCPK:(SZUKF), OTCPK:(ALPMY), OTCPK:(OTSKY), OTCPK:(CHGCY), OTCPK:(DSNKY), OTCPK:(OPHLY), OTCPK:(CHPTY), OTCPK:(SNPHY), OTCPK:(PTKFY) » details|
|Traded in other countries:||JNJ.Argentina, JNJB34.Brazil, JNJ.Chile, JNJ.Germany, JNJ.Mexico, JNJ.Switzerland, 0R34.UK,|
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of products in the health care field within its Consumer, Pharmaceutical and Medical Devices segments.
Johnson & Johnson is the world’s largest and most diverse healthcare company. Three divisions make up the company: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. About half of total revenue is generated within the United States.